Lower Dose of Polatuzumab Vedotin Safe And Effective In Follicular Lymphoma

Lower Dose of Polatuzumab Vedotin Safe And Effective In Follicular Lymphoma
0
(0)

Data recently presented at the ASCO Annual Meeting showed that a lower dose of polatuzumab vedotin in combination with rituximab has a similar overall response rate but improved toxicity when compared to a superior dose in patients with relapsed or refractory follicular lymphoma.

“Polatuzumab vedotin is an anti-CD79b antibody-drug conjugate,” Ranjana H. Advani, MD, professor of lymphoma at Stanford University, said in a recent news release. “CD79b is a component of the B-cell receptor and is expressed in nearly all B-cell malignancies. Clinical activity has been observed in relapsed and refractory non-Hodgkin’s lymphoma at doses greater than or equal to 1.8 mg/kg in a phase 1 trial. Subsequently, two dose levels — 1.8 mg/kg and 2.4 mg/kg — were assessed in a phase 2 trial in relapsed and refractory follicular lymphoma, but the optimal duration of therapy is unknown.”

In previous studies, patients treated with 2.4 mg/kg dose polatuzumab vedotin showed signs of toxicity. In this study researchers investigated if the combination of polatuzumab vedotin at lower doses was still therapeutically efficient and could decrease cumulative toxicity.

A total of 35 patients with relapsed or refractory follicular lymphoma who were treated with either 75 mg/m2 rituximab with 1.8 mg/kg (n = 10) or 2.4 mg/kg (n = 25) of polatuzumab vedotin were enrolled. The treatment was performed every 3 weeks and the results collected until there were signs of unacceptable toxicity. At the end, patients were submitted to at least eight treatment cycles, with a median follow-up of 8 and 14 months for 1.8-mg/kg and 2.4 mg/kg patients’ cohort, respectively.

Researchers observed that while the overall response rate was similar in both cohorts (75% for 1.8-mg/kg and 76% for 2.4-mg/kg), after eight treatment cycles, patients treated with the highest dose achieved higher complete response rates – 32% versus 10%. The adverse effects of grade 3 or higher occurred in both cohorts after eight cycles, however, at 2.4-mg/kg more patients discontinued the treatment due to an adverse event at eight cycles (28% versus 25%) and with treatment completion (56% versus 30%).

“Tolerability may be improved by dosing polatuzumab vedotin at 1.8 mg/kg and a fixed duration of eight or fewer cycles,” Advani said. “Efficacy is seen at both dose levels, despite the higher number of complete remission at the higher dose. Polatuzumab may represent a clinical meaningful treatment option at the 1.8-mg/kg dose at the fixed duration of therapy, and studies of this combination of immunotherapy are ongoing in both large cell lymphoma andfollicular lymphoma.”

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • ATG-019 Phase 1 trial
  • ME-401, FDA fast track
  • Tafasitamab combo, lymphoma
  • blood biomarkers

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?